- Outcomes and Factors Associated with Completion of Radium‑223 Therapy
-
Liu R, Juwara L, Ferrario C, Probst S
- KMID: 2534410
- Nucl Med Mol Imaging.
- 2022 Oct;56(5):228-235.
- doi: 10.1007/s13139-022-00760-8
Purpose Radium-223 has been demonstrated in clinical trials to improve survival in castration-resistant prostate cancer (CRPC) patients with bone metastases. However, its performance in routine use remains to be fully... -
- CITED
-
- Close
- SHARE
-
- Close
- Interval Changes in PSMA PET/CT During Radium‑223 Therapy for Metastatic Bone Disease from Castration‑Resistant Prostate Cancer
-
Probst S, Bjartell A, Anand A, Skamene T, Ferrario C
- KMID: 2532369
- Nucl Med Mol Imaging.
- 2022 Aug;56(4):188-195.
- doi: 10.1007/s13139-022-00754-6
Background Radium-223, an alpha-emitting therapeutic radiopharmaceutical, prolongs overall survival (OS) in patients with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT is a molecular imaging tool for whole-body imaging... -
- CITED
-
- Close
- SHARE
-
- Close
